Published in Vaccine Weekly, August 10th, 1998
The trial is being sponsored by the U.S. National Cancer Institute (NCI) under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery.
The experimental vaccine contains a gene which may cause cells at the injection site to produce a modified gp100 melanoma antigen. The antigen is expected to trigger an immune response against melanoma tumor cells. In earlier studies, Rosenberg tested a vaccine using peptides (portions of the modified...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly